TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.41B
EPS5.6000
P/E Ratio12.44
Earnings Date07/29/2026

tmdx

Total Equity

Last Annual Value

473.10M

3-Year CAGR

36%

5-Year CAGR

35%

10-Year CAGR

28%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of Total Equity

TMDX · NASDAQ
CompanyTotal Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
473.10M
51.1%47.5%28.4% 
750.11M
11.9%34.7%N/A
656.15M
12.4%2.2%18.8%
2.51B
21.1%18.3%13.6%
378.54M
-4.0%N/AN/A
1.58B
58.7%28.0%N/A
-98.00M
N/AN/AN/A
683.43M
33.3%64.6%N/A
980.74M
6.8%-6.8%N/A
1.33B
-2.3%2.4%N/A
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
852.59M
33.0%16.8%N/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $69.69, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $69.69